
Roche Pharma Research and Early Development lab automation specialist, Pawel Linke, discusses their approach to doubling the number of projects in process development without significantly increasing headcount.

Roche Pharma Research and Early Development lab automation specialist, Pawel Linke, discusses their approach to doubling the number of projects in process development without significantly increasing headcount.

This application note collection will help ensure you have the right tools to succeed in the biopharmaceutical environment, from research and process development to quality control.

The traditional packaging for frozen BDS applications has significant weaknesses at lower temperatures. This paper discusses new materials and freeze-thaw systems to meet these challenges.


An industrial biotechnology company in Denmark required more rigorous control measures to ensure a high level of bio-decontamination in its facility. An automated hydrogen peroxide vapor service from Bioquell was selected.


Glycosylation homogeneity and pattern can be increase with cell line engineering and bioprocess optimization. But, these can be time-consuming and might compromise yield. In vitro glycoengineering can solve these problems and is independent from the cell line and the bioprocess used.

Protect the integrity of your data with technologies that meet regulatory requirements for secure, accurate data capture and record-keeping.

In 2019, G-CON provided the cleanroom solution for GenCure’s new multi-product cell therapy facility. The new facility expands GenCure’s manufacturing capabilities, providing state-of-the-art manufacturing services to therapeutic developers.


High-density cell banking accelerates the upstream process by providing concentrated cells to jumpstart a production run. This intensification eliminates many laborious and risky steps used in most labs



Cerba Research initiated custom kit building and distribution for an infectious disease study, during the COVID-19 pandemic, in 10 days. A typical timeline is 8 weeks.

Bridging Anti-CHO HCP Antibodies from Two 3rd Generation Cygnus CHO HCP ELISA Kits by AAE-MS







For immuno-oncology trials, partner with a global central lab that can generate early insights to optimize your protocol and ramp up to commercial scale while preserving budgets and timelines.







